The Fifty-second World Health Assembly,Reca lling resolutions WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13 ,WHA47.16, WHA47.17, and WHA49.14;Having considered the report of the Director-General on the revised drug strategy;1Noting the activities of WHO to further the implementation of the revised drug strategy, in particula rthrough support to the development and implementation of national drug policies; the strategy to review an dassess the effectiveness of the WHO Ethical Criteria for Medicinal Drug Promotion; the flow of marke tinformation; guidelines for drug donations; and model drug information;Recognizing with satisfaction the progress made, and approving WHOs comprehensive response to currentand new challenges in the pharmaceutical sector;Commending the strong leadership shown by WHO in promoting the essential drugs concept and nationaldrug policies, which are contributing to the rational use of resources in the pharmaceutical sector and to improvedhealth care;Noting with satisfaction that a number of Member States have adopted guidelines for drug donations thatare based on the interagency guidelines issued by WHO, but concerned that inappropriate drug donations, suchas donati ons of expired, mislabelled, inessential products, continue tobe common, and further concerned tha tevaluation of the impact of the guidelines has not yet been completed;Concerned about the situation in which (a) one-third of the worlds population has no guaranteed accessto essential drugs, and (b) poor quality pharmaceutical raw materials and finished products continue to move ininternational trade;Noting that there are trade issues which require a public health perspective;WHA52.192Recognizing that the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) providesscope for the protection of public health;Taking note of concerns of many Member States about the impact of relevant international agreements,including trade agreements, on local manufacturing capacity and on access to and prices of pharmaceuticals indeveloping and least developed countries;Concerned also that drugs continue tobe irrationally used by p rescribers, dispensers and the general public,and that unethical promotion in developed and developing countries alack of access to independent ,scientifically validated drug information contribute to such abuse,1. URGES Member States:(1) to reaffirm their commitment to developing, implementing and monitoring national drug policies andto taking all necessary concrete measures in order to ensure equitable access to essential drugs;(2) to ensure that public health interests are paramount in pharmaceutical and health policies;(3) to explore and review their options under relevant international agreements, including trad eagreements, to safeguard access to essential drugs;(4) to establish and enforcer egulations that ensure good uniform standards of quality assurance for allpharmaceutical materi als and products manufactured in, imported to, exported from, or in transit throughtheir countries;(5) to enact and enforce legislation or regulat ions inaccordance with the principles of the WHO EthicalCriteria for Medicinal Drug Promotion, to encourage the pharmaceutical industry and the health communityto establish an ethical code, and to monitor drug promotion in collaboration with interested parties; (6) to develop or maintain national guidelines governing drug donations that are compatible with theinteragency guidelines issued by WHO and to work with all interested parties to promote adherence to suchguidelines;(7) to promote the rational use of drugs through the provision of independent, up-to-date an dcomparative drug information, and to integrate the rational use of drugs and information about commercialmarketing strategies into training for health practitioners at all levels;(8) to promote and support education of consumers in the rational use of drugs and its inclusion intoschool curricula;(9) to evaluate progress regularly, making use of indicators developed by WHO or of other suitabl emechanisms;(10) to continue their funding and material support for the revised drug strategy, especially through theprovision of extrabudgetary resources to WHO;WHA52.1932. REQUESTS the Director-General:(1) to support Member States in their efforts to develop and implement policies and programmes thatachieve the objectives of the revised drug strategy, including the development of tools, guidelines an dmethodology for evaluation and monitoring; (2) to adopt a comprehensive strategy to implement the WHO Ethical Criteria for Medicinal Dru gPromotion and to continue to review its effectiveness with all interested parties;(3) to extend the guidelines incorporated in the WHO Certification Scheme on the Quality o fPharmaceutical Products Moving in International Commerce to cover pharmaceutical starting materials;to develop and disseminate uniform guidelines on the regulatory control, export, import and transi tconditi ons of pharmaceutical products; and to develop standards of practice for entities involved i ninternational trade in pharmaceuticals and pharmaceutical starting materials;(4) to establish and develop a model inspection certificate for the national inspection of pharmaceuticalmanufactu ring sites of starting materials and finished pharmaceutical products in order to ensur ecomplia nce with WHO Good Manufacturing Practices, and to collaborate with Member States, at thei rrequest, in implementation;(5) to strengthen and expand the provision of independent information on market prices of startin gmaterials of assured quality for production of essential drugs;(6) to continue the development and dissemination, also using electronic media such as the Internet, ofindependent information on safety of pharmaceutical products and instances of counterfeit drugs o rmedicines, on drug selection and on rational prescribing;(7) to cooperate with Member States, at their request, and with international organizations in monitoringand analysing the pharmaceutical and public health implications of relevant international agreements ,including trade agreements, so that Member States can effectively assess and subsequently develo ppharmaceutical and health pol icies and regulatory measures that address their concerns and priorities, andare able to maximize the positive and mitigate the negative impact of those agreements;(8) to review and update the revised drug strategy to reflect current and continued challenges in th epharmaceutical sector and the principles articulated in the renewed health-for-all policy;(9) to report to the Fifty-third World Health Assembly on progress achieved and problems encounteredin the implementation and renewal of WHOs revised drug strategy, with recommendations for action.Ninth plenary meeting, 24 May 1999A52 / VR / 9